A Different Perspective of COVID-19 Pandemic: Efficacy and Safety of mRNA Vaccines in Immunocompetent and Immunocompromised Individuals (Part 3)
Exp Clin Transplant. 2024 Jan;22(Suppl 2):33-62. doi: 10.6002/ect.2023.0132.ABSTRACTShortly after the declaration of the pandemic, several anti-SARS-CoV-2 vaccines entered phase 3 clinical trials. One year later, Pfizer-BioNTech and Moderna published their initial trial results, encompassing a 2-month follow-up. The studies were only designed to test whether the vaccines were effective and safe on the short-term.The vaccine's efficacy in the 2 trials was defined as relative risk reduction instead of absolute risk reduction, a more accurate determinant of vaccine effectiveness in the real world. These studies were not desig...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 22, 2024 Category: Transplant Surgery Authors: Antoine Barbari Source Type: research
A Different Perspective on the COVID-19 Pandemic: Origin of the Outbreak (Part 1)
Exp Clin Transplant. 2024 Jan;22(Suppl 2):1-14. doi: 10.6002/ect.2023.0074.ABSTRACTIn December 2019, an outbreak caused by novel coronavirus 2019 (COVID-19) started in Wuhan, China. After extensive speculation about a causative agent, a novel betacoronavirus, in the same family as SARS-CoV and MERS-CoV, was identified via next-generation sequencing from samples received from several pneumonia patients. Ribonucleic acid extracted from the patient's bronchoalveolar lavage fluid was used as a template to clone and sequence the genome of SARS-CoV-2. Shortly after, the World Health Organization announced a worldwide pandemic. H...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 22, 2024 Category: Transplant Surgery Authors: Antoine Barbari Source Type: research
A Different Perspective of COVID-19 Pandemic: Efficacy and Safety of mRNA Vaccines in Immunocompetent and Immunocompromised Individuals (Part 3)
Exp Clin Transplant. 2024 Jan;22(Suppl 2):33-62. doi: 10.6002/ect.2023.0132.ABSTRACTShortly after the declaration of the pandemic, several anti-SARS-CoV-2 vaccines entered phase 3 clinical trials. One year later, Pfizer-BioNTech and Moderna published their initial trial results, encompassing a 2-month follow-up. The studies were only designed to test whether the vaccines were effective and safe on the short-term.The vaccine's efficacy in the 2 trials was defined as relative risk reduction instead of absolute risk reduction, a more accurate determinant of vaccine effectiveness in the real world. These studies were not desig...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 22, 2024 Category: Transplant Surgery Authors: Antoine Barbari Source Type: research
A Different Perspective on the COVID-19 Pandemic: Origin of the Outbreak (Part 1)
Exp Clin Transplant. 2024 Jan;22(Suppl 2):1-14. doi: 10.6002/ect.2023.0074.ABSTRACTIn December 2019, an outbreak caused by novel coronavirus 2019 (COVID-19) started in Wuhan, China. After extensive speculation about a causative agent, a novel betacoronavirus, in the same family as SARS-CoV and MERS-CoV, was identified via next-generation sequencing from samples received from several pneumonia patients. Ribonucleic acid extracted from the patient's bronchoalveolar lavage fluid was used as a template to clone and sequence the genome of SARS-CoV-2. Shortly after, the World Health Organization announced a worldwide pandemic. H...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 22, 2024 Category: Transplant Surgery Authors: Antoine Barbari Source Type: research
A Different Perspective of COVID-19 Pandemic: Efficacy and Safety of mRNA Vaccines in Immunocompetent and Immunocompromised Individuals (Part 3)
Exp Clin Transplant. 2024 Jan;22(Suppl 2):33-62. doi: 10.6002/ect.2023.0132.ABSTRACTShortly after the declaration of the pandemic, several anti-SARS-CoV-2 vaccines entered phase 3 clinical trials. One year later, Pfizer-BioNTech and Moderna published their initial trial results, encompassing a 2-month follow-up. The studies were only designed to test whether the vaccines were effective and safe on the short-term.The vaccine's efficacy in the 2 trials was defined as relative risk reduction instead of absolute risk reduction, a more accurate determinant of vaccine effectiveness in the real world. These studies were not desig...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 22, 2024 Category: Transplant Surgery Authors: Antoine Barbari Source Type: research
A Different Perspective on the COVID-19 Pandemic: Origin of the Outbreak (Part 1)
Exp Clin Transplant. 2024 Jan;22(Suppl 2):1-14. doi: 10.6002/ect.2023.0074.ABSTRACTIn December 2019, an outbreak caused by novel coronavirus 2019 (COVID-19) started in Wuhan, China. After extensive speculation about a causative agent, a novel betacoronavirus, in the same family as SARS-CoV and MERS-CoV, was identified via next-generation sequencing from samples received from several pneumonia patients. Ribonucleic acid extracted from the patient's bronchoalveolar lavage fluid was used as a template to clone and sequence the genome of SARS-CoV-2. Shortly after, the World Health Organization announced a worldwide pandemic. H...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 22, 2024 Category: Transplant Surgery Authors: Antoine Barbari Source Type: research
A Different Perspective of COVID-19 Pandemic: Efficacy and Safety of mRNA Vaccines in Immunocompetent and Immunocompromised Individuals (Part 3)
Exp Clin Transplant. 2024 Jan;22(Suppl 2):33-62. doi: 10.6002/ect.2023.0132.ABSTRACTShortly after the declaration of the pandemic, several anti-SARS-CoV-2 vaccines entered phase 3 clinical trials. One year later, Pfizer-BioNTech and Moderna published their initial trial results, encompassing a 2-month follow-up. The studies were only designed to test whether the vaccines were effective and safe on the short-term.The vaccine's efficacy in the 2 trials was defined as relative risk reduction instead of absolute risk reduction, a more accurate determinant of vaccine effectiveness in the real world. These studies were not desig...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 22, 2024 Category: Transplant Surgery Authors: Antoine Barbari Source Type: research
A Different Perspective on the COVID-19 Pandemic: Origin of the Outbreak (Part 1)
Exp Clin Transplant. 2024 Jan;22(Suppl 2):1-14. doi: 10.6002/ect.2023.0074.ABSTRACTIn December 2019, an outbreak caused by novel coronavirus 2019 (COVID-19) started in Wuhan, China. After extensive speculation about a causative agent, a novel betacoronavirus, in the same family as SARS-CoV and MERS-CoV, was identified via next-generation sequencing from samples received from several pneumonia patients. Ribonucleic acid extracted from the patient's bronchoalveolar lavage fluid was used as a template to clone and sequence the genome of SARS-CoV-2. Shortly after, the World Health Organization announced a worldwide pandemic. H...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 22, 2024 Category: Transplant Surgery Authors: Antoine Barbari Source Type: research
A Different Perspective of COVID-19 Pandemic: Efficacy and Safety of mRNA Vaccines in Immunocompetent and Immunocompromised Individuals (Part 3)
Exp Clin Transplant. 2024 Jan;22(Suppl 2):33-62. doi: 10.6002/ect.2023.0132.ABSTRACTShortly after the declaration of the pandemic, several anti-SARS-CoV-2 vaccines entered phase 3 clinical trials. One year later, Pfizer-BioNTech and Moderna published their initial trial results, encompassing a 2-month follow-up. The studies were only designed to test whether the vaccines were effective and safe on the short-term.The vaccine's efficacy in the 2 trials was defined as relative risk reduction instead of absolute risk reduction, a more accurate determinant of vaccine effectiveness in the real world. These studies were not desig...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 22, 2024 Category: Transplant Surgery Authors: Antoine Barbari Source Type: research
A Different Perspective on the COVID-19 Pandemic: Origin of the Outbreak (Part 1)
Exp Clin Transplant. 2024 Jan;22(Suppl 2):1-14. doi: 10.6002/ect.2023.0074.ABSTRACTIn December 2019, an outbreak caused by novel coronavirus 2019 (COVID-19) started in Wuhan, China. After extensive speculation about a causative agent, a novel betacoronavirus, in the same family as SARS-CoV and MERS-CoV, was identified via next-generation sequencing from samples received from several pneumonia patients. Ribonucleic acid extracted from the patient's bronchoalveolar lavage fluid was used as a template to clone and sequence the genome of SARS-CoV-2. Shortly after, the World Health Organization announced a worldwide pandemic. H...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 22, 2024 Category: Transplant Surgery Authors: Antoine Barbari Source Type: research
A Different Perspective of COVID-19 Pandemic: Efficacy and Safety of mRNA Vaccines in Immunocompetent and Immunocompromised Individuals (Part 3)
Exp Clin Transplant. 2024 Jan;22(Suppl 2):33-62. doi: 10.6002/ect.2023.0132.ABSTRACTShortly after the declaration of the pandemic, several anti-SARS-CoV-2 vaccines entered phase 3 clinical trials. One year later, Pfizer-BioNTech and Moderna published their initial trial results, encompassing a 2-month follow-up. The studies were only designed to test whether the vaccines were effective and safe on the short-term.The vaccine's efficacy in the 2 trials was defined as relative risk reduction instead of absolute risk reduction, a more accurate determinant of vaccine effectiveness in the real world. These studies were not desig...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 22, 2024 Category: Transplant Surgery Authors: Antoine Barbari Source Type: research
A Different Perspective on the COVID-19 Pandemic: Origin of the Outbreak (Part 1)
Exp Clin Transplant. 2024 Jan;22(Suppl 2):1-14. doi: 10.6002/ect.2023.0074.ABSTRACTIn December 2019, an outbreak caused by novel coronavirus 2019 (COVID-19) started in Wuhan, China. After extensive speculation about a causative agent, a novel betacoronavirus, in the same family as SARS-CoV and MERS-CoV, was identified via next-generation sequencing from samples received from several pneumonia patients. Ribonucleic acid extracted from the patient's bronchoalveolar lavage fluid was used as a template to clone and sequence the genome of SARS-CoV-2. Shortly after, the World Health Organization announced a worldwide pandemic. H...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 22, 2024 Category: Transplant Surgery Authors: Antoine Barbari Source Type: research
A Different Perspective of COVID-19 Pandemic: Efficacy and Safety of mRNA Vaccines in Immunocompetent and Immunocompromised Individuals (Part 3)
Exp Clin Transplant. 2024 Jan;22(Suppl 2):33-62. doi: 10.6002/ect.2023.0132.ABSTRACTShortly after the declaration of the pandemic, several anti-SARS-CoV-2 vaccines entered phase 3 clinical trials. One year later, Pfizer-BioNTech and Moderna published their initial trial results, encompassing a 2-month follow-up. The studies were only designed to test whether the vaccines were effective and safe on the short-term.The vaccine's efficacy in the 2 trials was defined as relative risk reduction instead of absolute risk reduction, a more accurate determinant of vaccine effectiveness in the real world. These studies were not desig...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 22, 2024 Category: Transplant Surgery Authors: Antoine Barbari Source Type: research
A Different Perspective on the COVID-19 Pandemic: Origin of the Outbreak (Part 1)
Exp Clin Transplant. 2024 Jan;22(Suppl 2):1-14. doi: 10.6002/ect.2023.0074.ABSTRACTIn December 2019, an outbreak caused by novel coronavirus 2019 (COVID-19) started in Wuhan, China. After extensive speculation about a causative agent, a novel betacoronavirus, in the same family as SARS-CoV and MERS-CoV, was identified via next-generation sequencing from samples received from several pneumonia patients. Ribonucleic acid extracted from the patient's bronchoalveolar lavage fluid was used as a template to clone and sequence the genome of SARS-CoV-2. Shortly after, the World Health Organization announced a worldwide pandemic. H...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 22, 2024 Category: Transplant Surgery Authors: Antoine Barbari Source Type: research
A Different Perspective of COVID-19 Pandemic: Efficacy and Safety of mRNA Vaccines in Immunocompetent and Immunocompromised Individuals (Part 3)
Exp Clin Transplant. 2024 Jan;22(Suppl 2):33-62. doi: 10.6002/ect.2023.0132.ABSTRACTShortly after the declaration of the pandemic, several anti-SARS-CoV-2 vaccines entered phase 3 clinical trials. One year later, Pfizer-BioNTech and Moderna published their initial trial results, encompassing a 2-month follow-up. The studies were only designed to test whether the vaccines were effective and safe on the short-term.The vaccine's efficacy in the 2 trials was defined as relative risk reduction instead of absolute risk reduction, a more accurate determinant of vaccine effectiveness in the real world. These studies were not desig...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 22, 2024 Category: Transplant Surgery Authors: Antoine Barbari Source Type: research
